FIGURE 5.

Immunity‐and‐matrix regulatory cell (IMRC) treatment does not alter the development of amyloid‐beta (Aβ)‐pathology in 5×FAD mice. (A), (B), Representative images of thioflavin‐S staining (A) and quantification (B) of the numbers and areas of Aβ plaques in the cortex and hippocampus; 5×FAD^M‐IV, intravenous (IV) IMRC administration; 5×FAD^M‐ICV, intracerebroventricular (ICV) IMRC administration; 5×FAD^NaCl, IV NaCl treatment. n = 16 to 19 slices from 3 mice per group; data represent means ± SEM; one‐way ANOVA with Tukey's multiple comparison test; n.s., nonsignificant. Scale bars: 50 μm (upper); 100 μm (lower). (C), (D), Representative Western blots (C) and relative quantification (D) of Aβ expression levels in cortical tissues from each group. There was no significant reduction in Aβ deposition in 5×FAD mice (n = 3 mice per group; data represent means ± SEM; one‐way ANOVA with Tukey's correction; n.s., nonsignificant)